BRUERA, GEMMA

BRUERA, GEMMA  

Dipartimento di Scienze cliniche applicate e biotecnologiche  

Mostra records
Risultati 1 - 20 di 25 (tempo di esecuzione: 0.065 secondi).
Titolo Data di pubblicazione Autore(i) File
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 1-gen-2022 Guadagni, Stefano; Masedu, Francesco; Fiorentini, Giammaria; Sarti, Donatella; Fiorentini, Caterina; Guadagni, Veronica; Apostolou, Panagiotis; Papasotiriou, Ioannis; Parsonidis, Panagiotis; Valenti, Marco; Ricevuto, Enrico; Bruera, Gemma; Farina, Antonietta R; Mackay, Andrew R; Clementi, Marco
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 1-gen-2017 Bruera, Gemma; Russo, Antonio; Galvano, Antonio; Rizzo, Sergio; Ricevuto, Enrico
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 1-gen-2015 Ricevuto, Enrico; Cocciolone, Valentina; Mancini, MARIA VINCENZA; Cannita, Katia; Romano, Silvio; Bruera, Gemma; Pelliccione, Michela; Adinolfi, Maria Ilaria; Ciccozzi, Antonietta; Bafile, Alberto; Penco, Maria; Ficorella, Corrado
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 1-gen-2018 Bruera, Gemma; Di Staso, Mario; Bonfili, Pierluigi; Galvano, Antonio; Manetta, Rosa; Coletti, Gino; Vicentini, Roberto; Guadagni, Stefano; Ficorella, Corrado; DI CESARE, Ernesto; Ricevuto, Enrico
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 1-gen-2013 Bruera, Gemma; Cannita, K; Giordano, Av; Vicentini, R; Ficorella, Corrado; Ricevuto, Enrico
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 1-gen-2012 Bruera, Gemma; Cannita, K; Giuliante, F; Lanfiuti Baldi, P; Vicentini, R; Marchetti, P; Nuzzo, G; Antonucci, A; Ficorella, Corrado; Ricevuto, Enrico
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 1-gen-2011 Bruera, Gemma; Ricevuto, Enrico
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 1-gen-2019 Bruera, Gemma; Massacese, Silvia; Pepe, Francesco; Malapelle, Umberto; Dal Mas, Antonella; Ciacco, Eugenio; Calvisi, Giuseppe; Troncone, Giancarlo; Simmaco, Maurizio; Ricevuto, Enrico
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice 1-gen-2021 Bruera, Gemma; Pepe, Francesco; Malapelle, Umberto; Di Staso, Mario; Dal Mas, Antonella; Di Giacomo, Daniela; Scerbo, Gaia; Santilli, Michela; Ciacco, Eugenio; Simmaco, Maurizio; Troncone, Giancarlo; Coco, Claudio; Giuliante, Felice; Ricevuto, Enrico
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 1-gen-2018 Tessitore, A; Bruera, G; Mastroiaco, V; Cannita, K; Cortellini, A; Cocciolone, V; Dal Mas, A; Calvisi, G; Zazzeroni, F; Ficorella, C; Ricevuto, E; Alesse, E
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 1-gen-2018 Bruera, Gemma; Francesco, Pepe; Umberto, Malapelle; Pasquale, Pisapia; Antonella Dal Mas, ; DI GIACOMO, Daniela; Calvisi, Giuseppe; Giancarlo, Troncone; Ricevuto, Enrico
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 1-gen-2012 Tudini, Marianna; Palluzzi, Eleonora; Cannita, Katia; Mancini, Maria; Santomaggio, Alessandra; Bruera, Gemma; Baldi, Paola Lanfiuti; Pelliccione, Michela; Ricevuto, Enrico; Ficorella, Corrado
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 1-gen-2019 Guadagni, S.; Fiorentini, G.; Mambrini, A.; Masedu, F.; Valenti, M.; Mackay, A. R.; Sarti, D.; Ricevuto, E.; Clementi, M.; Catarci, M.; Lazzarin, Gianni; Bruera, G.
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 1-gen-2020 Guadagni, Stefano; Farina, Antonietta; Cappabianca, LUCIA ANNAMARIA; Sebastiano, Michela; Maccarone, Rita; Zelli, Veronica; Clementi, Marco; Chiominto, Alessandro; Bruera, Gemma; Ricevuto, Enrico; Fiorentini, Giammaria; Sarti, Donatella; Mackay, ANDREW REAY
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments 1-gen-2020 Bruera, Gemma; Ricevuto, Enrico
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice 1-gen-2019 Bruera, G.; Giuliani, A.; Romano, L.; Chiominto, A.; Di Sibio, A.; Mastropietro, S.; Cosenza, P.; Ricevuto, E.; Schietroma, M.; Carlei, F.
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 1-gen-2015 Bruera, Gemma; Cannita, K; Tessitore, Alessandra; Russo, A; Alesse, Edoardo; Ficorella, Corrado; Ricevuto, Enrico
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 1-gen-2018 Bruera, G.; Massacese, S.; Candria, S.; Galvano, A.; Manetta, R.; Giordano, A. V.; Carducci, S.; Di Sibio, A.; Ciacco, E.; Russo, A.; Ricevuto, E.
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 1-gen-2020 Guadagni, S.; Clementi, M.; Mackay, A. R.; Ricevuto, E.; Fiorentini, G.; Sarti, D.; Palumbo, P.; Apostolou, P.; Papasotiriou, I.; Masedu, F.; Valenti, M.; Giordano, A. V.; Bruera, G.
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 1-gen-2020 Bruera, G; D'Andrilli, A; Simmaco, M; Guadagni, S; Rendina, Ea; Ricevuto, E